Thrive Wealth Management LLC Purchases 110 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Thrive Wealth Management LLC raised its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.4% during the first quarter, HoldingsChannel.com reports. The firm owned 1,076 shares of the medical research company’s stock after purchasing an additional 110 shares during the period. Thrive Wealth Management LLC’s holdings in Charles River Laboratories International were worth $292,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in CRL. Vanguard Group Inc. raised its holdings in shares of Charles River Laboratories International by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 5,980,306 shares of the medical research company’s stock worth $1,413,744,000 after buying an additional 26,446 shares during the period. Meritage Group LP grew its position in Charles River Laboratories International by 30.8% in the 4th quarter. Meritage Group LP now owns 1,155,376 shares of the medical research company’s stock valued at $273,131,000 after acquiring an additional 271,743 shares during the last quarter. Ariel Investments LLC increased its stake in Charles River Laboratories International by 1.8% in the third quarter. Ariel Investments LLC now owns 1,066,600 shares of the medical research company’s stock worth $209,032,000 after purchasing an additional 18,760 shares during the period. Earnest Partners LLC lifted its position in shares of Charles River Laboratories International by 5.5% during the third quarter. Earnest Partners LLC now owns 805,883 shares of the medical research company’s stock worth $157,937,000 after purchasing an additional 41,689 shares during the last quarter. Finally, FIL Ltd grew its holdings in shares of Charles River Laboratories International by 23.2% in the fourth quarter. FIL Ltd now owns 662,650 shares of the medical research company’s stock worth $156,650,000 after purchasing an additional 125,000 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction on Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the sale, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Up 0.3 %

Shares of CRL traded up $0.66 during midday trading on Thursday, hitting $207.37. 292,425 shares of the company’s stock traded hands, compared to its average volume of 542,876. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The firm’s fifty day moving average is $220.57 and its 200-day moving average is $232.48. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $10.68 billion, a price-to-earnings ratio of 24.40, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. The Goldman Sachs Group initiated coverage on shares of Charles River Laboratories International in a research note on Thursday, June 6th. They issued a “buy” rating and a $290.00 target price on the stock. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, June 14th. Mizuho assumed coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They issued a “neutral” rating and a $235.00 price target for the company. Robert W. Baird reduced their price objective on shares of Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Finally, TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $256.38.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).